Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.

ABSTRACT: Alternative splicing (AS) is a critical post-transcriptional regulatory mechanism used by more than 95% of transcribed human genes and responsible for structural transcript variation and proteome diversity. In the past decade, genome-wide transcriptome sequencing has revealed that AS is tightly regulated in a tissue- and developmental stage-specific manner, and also frequently dysregulated in multiple human cancer types. It is currently recognized that splicing defects, including genetic alterations in the spliced gene, altered expression of both core components or regulators of the precursor messenger RNA (pre-mRNA) splicing machinery, or both, are major drivers of tumorigenesis. Hence, in this review we provide an overview of our current understanding of splicing alterations in cancer, a

SUBMITTER: Bessa C 

PROVIDER: S-EPMC7729450 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature